|
|
 |
|
CALGB 80405 A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum. Adenocarcinoma of the Colon or Rectum
CALGB 80405 - PDF
E5202 A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin vs 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients With Stage II Colon Cancer at High Risk for Recurrence, to Determine Prospectively the Prognostic Value of Molecular Markers
E5202 - PDF
Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Pre-operative Chemoradiation
E5204 - PDF
A Randomized Phase III Trial of Oxaliplatin Plus 5-FU/Leucovorin with or without Cetuximab after Curative Resection for Patients with Stage III Colon Cancer
N0147 - PDF
A Clinical Trial Comparing Preoperative Radiation Therapy And Capecitabine with Preoperative Radiation Therapy And Continuous Intravenous Infusion (CVI) of 5-Fluorouracil (5-FU) in The Treatment of Patients With Operable Carcinoma of The Rectum
NSABP R-04 - PDF
Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab (NSC-714682) With or Without Bevacizumab (NSC-704965) As Second-Line Therapy for Patients With Metastatic Colorectal Cancer Who Have Progressed on Bevacizumab With Either FOLFOX, OPTIMOX or XELOX
S0600 - PDF
« Back | Top
|
|
|
|
|
|
